RU2427375C2 - Способы терапевтического применения стероидных соединений - Google Patents

Способы терапевтического применения стероидных соединений Download PDF

Info

Publication number
RU2427375C2
RU2427375C2 RU2008124834/15A RU2008124834A RU2427375C2 RU 2427375 C2 RU2427375 C2 RU 2427375C2 RU 2008124834/15 A RU2008124834/15 A RU 2008124834/15A RU 2008124834 A RU2008124834 A RU 2008124834A RU 2427375 C2 RU2427375 C2 RU 2427375C2
Authority
RU
Russia
Prior art keywords
pain
neuropathic pain
galanin
androsten
dione
Prior art date
Application number
RU2008124834/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008124834A (ru
Inventor
Эрнст ВЮЛЬФЕРТ (BE)
Эрнст ВЮЛЬФЕРТ
Джеймс Роберт МЮРРЕЙ (GB)
Джеймс Роберт МЮРРЕЙ
Дэвид УАЙНИК (GB)
Дэвид УАЙНИК
Original Assignee
Хантер-Флеминг Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Хантер-Флеминг Лимитед filed Critical Хантер-Флеминг Лимитед
Publication of RU2008124834A publication Critical patent/RU2008124834A/ru
Application granted granted Critical
Publication of RU2427375C2 publication Critical patent/RU2427375C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
RU2008124834/15A 2005-11-18 2006-11-17 Способы терапевтического применения стероидных соединений RU2427375C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0523550.2 2005-11-18
GBGB0523550.2A GB0523550D0 (en) 2005-11-18 2005-11-18 Therapeutic uses of steroidal compounds

Publications (2)

Publication Number Publication Date
RU2008124834A RU2008124834A (ru) 2009-12-27
RU2427375C2 true RU2427375C2 (ru) 2011-08-27

Family

ID=35580318

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008124834/15A RU2427375C2 (ru) 2005-11-18 2006-11-17 Способы терапевтического применения стероидных соединений

Country Status (16)

Country Link
US (1) US8846652B2 (https=)
EP (1) EP1948192A2 (https=)
JP (1) JP5395437B2 (https=)
KR (1) KR101314694B1 (https=)
CN (1) CN101346144B (https=)
AU (1) AU2006314226B2 (https=)
CA (1) CA2630441C (https=)
GB (1) GB0523550D0 (https=)
IL (1) IL191457A (https=)
MX (1) MX2008006440A (https=)
NO (1) NO20082741L (https=)
NZ (1) NZ568560A (https=)
RU (1) RU2427375C2 (https=)
TW (1) TWI386211B (https=)
WO (1) WO2007057691A2 (https=)
ZA (1) ZA200804266B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745868C1 (ru) * 2020-05-28 2021-04-02 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU20110244A7 (es) 2011-12-27 2013-08-29 Ct De Investigación Y Desarrollo De Medicamentos Cidem Sistemas espiroesteroidales con efectos neuroactivos y anti-inflamatorios
CN108434090A (zh) * 2017-02-14 2018-08-24 高药品股份有限公司 以生理脂肪为基剂的类固醇药膏

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036129A2 (de) * 2000-11-02 2002-05-10 Alfred Schmidt Topische behandlung von mastalgie mit aromatase-hemmern, wie androstendion
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
WO2005105104A1 (en) * 2004-04-28 2005-11-10 Hunter-Fleming Limited Transdermal steroid formulation

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012997A1 (en) 1991-01-16 1992-08-06 The General Hospital Corporation Human galanin
WO1992015015A1 (en) 1991-02-25 1992-09-03 Zymogenetic, Inc. Methods for detecting galanin antagonists
DE69225706T2 (de) 1991-03-06 1998-11-26 Garvan Institute Of Medical Research, Darlinghurst, Neu Sued Wales/New South Wales Humanes galanin, cdna-klone die für humanes galanin kodieren und eine methode humanes galamin herzustellen
SE9101472D0 (sv) 1991-05-15 1991-05-15 Trion Forskning & Utveckling Galanin antagonist
JPH06172387A (ja) 1992-12-11 1994-06-21 Aibaitsu Kk 合成ペプチド誘導体
EP0698612B1 (en) * 1993-05-18 2001-07-25 Ltt Institute Co., Ltd. Osteogenesis promoter and osteoporosis remedy
JPH09151197A (ja) * 1995-11-29 1997-06-10 L T T Kenkyusho:Kk 自己免疫疾患治療薬
DE69739760D1 (de) 1996-07-24 2010-03-25 Neurotargets Ltd Verwendung eines Galanin-agonisten in der Herstellung eines Medikaments zur Verbesserung des Gedächtnisses und anderer cognitiver Funktionen
JP2000169374A (ja) * 1998-12-03 2000-06-20 Ltt Kenkyusho:Kk Ｉｇｆ増強剤
TR200200406T2 (tr) * 1999-06-11 2002-06-21 Watson Pharmaceuticals, Inc. Kadınlara oral olmayan yollarla androjenik steroidlerin uygulanması
DE60120104T2 (de) 2001-03-20 2006-09-21 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
WO2002096934A1 (en) 2001-05-25 2002-12-05 Kemia, Inc. Non-natural galanin receptor ligands
DK1406606T3 (da) 2001-07-16 2007-03-05 Ortho Mcneil Pharm Inc Carbamatforbindelser til forebyggelse eller behandling af neuropatisk smerte og smerte forbundet med klynge- og migrænehovedpine
JP2004538305A (ja) 2001-07-31 2004-12-24 ファルマシア・アンド・アップジョン・カンパニー ３−ヘテロシクリル−及び３−シクロアルキル−３−アリールオキシプロパンアミンによる慢性疼痛の治療
WO2003011272A1 (en) 2001-07-31 2003-02-13 Pharmacia & Upjohn Company Treatment of chronic pain with 3-aryloxy-3-phenylpropanamines
ATE332688T1 (de) 2001-10-16 2006-08-15 Endo Pharmaceuticals Inc Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
GB0403509D0 (en) 2004-02-17 2004-03-24 Neuro Targets Ltd Galanin receptors and brain injury
JP5449775B2 (ja) * 2005-10-19 2014-03-19 チャバフ ピーティーワイ エルティーディー 乳癌の治療に使用されるアロマターゼ阻害薬による副作用の低減
WO2008065408A2 (en) 2006-11-30 2008-06-05 Hunter-Fleming Limited Modulation of prostaglandin/cyclooxygenase metabolic pathways

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002036129A2 (de) * 2000-11-02 2002-05-10 Alfred Schmidt Topische behandlung von mastalgie mit aromatase-hemmern, wie androstendion
WO2002072084A2 (en) * 2001-03-08 2002-09-19 Sterix Limited Glycyrrhetinic acid derivatives, progesterone and progesterone derivatives and their use for the manufacture of a medicament to inhibit 11beta-hydroxysteroid dehydrogenase activity
WO2005105104A1 (en) * 2004-04-28 2005-11-10 Hunter-Fleming Limited Transdermal steroid formulation

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2745868C1 (ru) * 2020-05-28 2021-04-02 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах
RU2745868C9 (ru) * 2020-05-28 2021-04-08 Федеральное государственное бюджетное образовательное учреждение высшего образования «Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва» Способ ускорения регенерационных процессов в поврежденных периферических нервах

Also Published As

Publication number Publication date
US8846652B2 (en) 2014-09-30
MX2008006440A (es) 2008-12-01
RU2008124834A (ru) 2009-12-27
JP5395437B2 (ja) 2014-01-22
WO2007057691A2 (en) 2007-05-24
TW200730180A (en) 2007-08-16
NZ568560A (en) 2010-11-26
CN101346144A (zh) 2009-01-14
IL191457A (en) 2013-10-31
AU2006314226A1 (en) 2007-05-24
WO2007057691A3 (en) 2007-08-02
CA2630441C (en) 2013-10-29
CN101346144B (zh) 2011-07-20
US20090227551A1 (en) 2009-09-10
ZA200804266B (en) 2009-01-28
CA2630441A1 (en) 2007-05-24
GB0523550D0 (en) 2005-12-28
JP2009515939A (ja) 2009-04-16
TWI386211B (zh) 2013-02-21
IL191457A0 (en) 2009-08-03
KR101314694B1 (ko) 2013-10-07
NO20082741L (no) 2008-07-23
KR20080073755A (ko) 2008-08-11
EP1948192A2 (en) 2008-07-30
AU2006314226B2 (en) 2012-02-02

Similar Documents

Publication Publication Date Title
KR20090010161A (ko) 시클로리그난의 제2형 당뇨병의 치료를 위한, 그리고 피임약으로서의 용도
US9034826B2 (en) Use of epidermal growth factor for the morphofunctional restoration of peripheral nerves in diabetic neuropathy
AU2003250892B2 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
Wang et al. Human breast milk-derived exosomes protect against intestinal ischemia and reperfusion injury in neonatal rats
KR20050057673A (ko) Ｊｎｋ 억제제를 이용한 통증의 치료
US20100152150A1 (en) The application of marine steroid in preparing the medicine of treating neurons damaging
Harvey et al. Midkine and retinoic acid reduce cerebral infarction induced by middle cerebral artery ligation in rats
EA032569B1 (ru) Применение декстрансульфата, имеющего среднюю молекулярную массу mот 4500 до 7500 да, для индуцирования ангиогенеза у субъекта
RU2427375C2 (ru) Способы терапевтического применения стероидных соединений
McNeil et al. Reversal of ethanol and indomethacin‐induced suppression of hepatic DNA synthesis by 16, 16‐dimethyl prostaglandin E2
WO2018166404A1 (zh) 雷公藤红素用于预防和/或治疗胆汁淤积性肝病以及肝纤维化的用途
US20220257716A1 (en) Methods and compositions for the treatment of secretory disorders
JP2009515939A5 (https=)
WO2020125091A1 (zh) 南瓜籽油中甾醇组合物及其应用和治疗前列腺增生药物
CN116115760A (zh) Eed抑制剂在制备治疗神经免疫性疾病药物中的应用
WO2021102124A1 (en) Methods of inducing or enhancing farnesoid x receptor (fxr)-mediated transcriptional response
US8722707B1 (en) Compositions and methods for inhibition of smooth muscle cell proliferation and neointimal hyperplasia
US20060009432A1 (en) Use of neurosteroids to treat neuropathic pain
FR2930156A1 (fr) Utilisation du nonapeptide pat dans le traitement des maladies autoimmunes.
WO2007123234A1 (ja) 抗てんかん作用増強剤
EP1490069B1 (en) Alpha aed and beta aed regulation of nuclear transcription, gene regulation, and/or gene expression
JP2016509590A (ja) 加齢に伴う障害の治療のための組換え７型コラーゲンの投与
HK40060507B (zh) 包含环（组氨酸-脯氨酸）二肽及甲状旁腺激素的组合物用於预防、改善或治疗骨质流失疾病的用途
Buisson Bordet et a

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20161118